Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multi-center, Open-label, Single-arm, Before and After Switch Study to Evaluate the Efficacy, Safety and Tolerability of Alemtuzumab in Paediatric Patients With Relapsing Remitting Multiple Sclerosis (RRMS) With Disease Activity on Prior Disease Modifying Therapy (DMT)

Next Previous
Trial Profile

A Multi-center, Open-label, Single-arm, Before and After Switch Study to Evaluate the Efficacy, Safety and Tolerability of Alemtuzumab in Paediatric Patients With Relapsing Remitting Multiple Sclerosis (RRMS) With Disease Activity on Prior Disease Modifying Therapy (DMT)

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 10 Dec 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Alemtuzumab (Primary) ; Aciclovir; Cetirizine; Dexchlorpheniramine; Diphenhydramine; Glatiramer acetate; Histamine H1 receptor antagonists; Histamine H1 receptor antagonists; Histamine H2 receptor antagonists; Interferon beta; Interferon beta; Methylprednisolone; Paracetamol; Prednisolone; Ranitidine
  • Indications Multiple sclerosis
  • Focus Therapeutic Use
  • Acronyms LemKids
  • Sponsors Sanofi Genzyme

Most Recent Events

  • 26 Nov 2025 Status changed from active, no longer recruiting to discontinued.
  • 01 Jan 2025 Results evaluating the efficacy, safety, and tolerability of alemtuzumab in pediatric patients with relapsing-remitting multiple sclerosis (RRMS) and disease activity on prior disease-modifying therapies published in the Multiple Sclerosis Journal.
  • 10 Jan 2024 This trial has been completed in Poland, according to European Clinical Trials Database record.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top